Spots Global Cancer Trial Database for Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
Official Title: Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
Study ID: NCT04883827
Conditions
Study Description
Brief Summary: This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
Detailed Description: Primary Objective: - Evaluate tumor cell free (cf)DNA as a dynamic marker of response to immuno-oncology (IO) therapy Exploratory Objective: - Collect data on somatic mutations in cfDNA to gain insight into the biology of IO-responders and -non-responders
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Tennessee Valley Health Care System, Nashville, Tennessee, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Scott Haake, MD
Affiliation: Vanderbilt Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
